Summary
12.84 -1.03(-7.42%)07/02/2024
Stoke Therapeutics Inc (STOK)
Stoke Therapeutics Inc (STOK)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -7.22 | -7.95 | -16.97 | -1.19 | 118.76 | 20.46 | -55.09 | -49.78 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 12.84 | |
| Open | 13.67 | |
| High | 13.94 | |
| Low | 12.81 | |
| Volume | 442,032 | |
| Change | -1.00 | |
| Change % | -7.22 | |
| Avg Volume (20 Days) | 454,815 | |
| Volume/Avg Volume (20 Days) Ratio | 0.97 | |
| 52 Week Range | 3.35 - 17.58 | |
| Price vs 52 Week High | -26.96% | |
| Price vs 52 Week Low | 283.31% | |
| Range | -6.06 | |
| Gap Up/Down | -0.34 | |
Fundamentals | ||
| Market Capitalization (Mln) | 723 | |
| EBIDTA | -22,302,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 58.70 | |
| Book Value | 6.4580 | |
| Earnings Per Share | -2.0910 | |
| EPS Estimate Current Quarter | -0.5900 | |
| EPS Estimate Next Quarter | -0.6000 | |
| EPS Estimate Current Year | -2.3000 | |
| EPS Estimate Next Year | -2.6400 | |
| Diluted EPS (TTM) | -2.0910 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | -0.2097 | |
| Return on equity (TTM) | -0.3531 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.0794 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 36,791,000 | |
| Shares Float | 13,860,271 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 45.89 | |
| Institutions (%) | 52.99 | |
06/18 16:30 EST - businesswire.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on June 17, 2024, the company granted stock options to purchase an aggregate of 10,400 shares of common stock to one new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on June 17, 2024, the company granted stock options to purchase an aggregate of 10,400 shares of common stock to one new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options.
06/14 12:10 EST - seekingalpha.com
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and autosomal dominant optic atrophy (ADOA). STK-001, a Phase 1/2 candidate for Dravet syndrome, shows promising clinical results with seizure reduction and cognitive improvements.
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and autosomal dominant optic atrophy (ADOA). STK-001, a Phase 1/2 candidate for Dravet syndrome, shows promising clinical results with seizure reduction and cognitive improvements.
06/03 16:30 EST - businesswire.com
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldman Sachs 45th Annual Global Healthcare Conference Date: Monday, June 10, 2024 Time: 4:00 p.m. ET TD Cowen Genetic Medicines & RNA Summit Date: Thursday, June 20, 2024 Time: 1.
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldman Sachs 45th Annual Global Healthcare Conference Date: Monday, June 10, 2024 Time: 4:00 p.m. ET TD Cowen Genetic Medicines & RNA Summit Date: Thursday, June 20, 2024 Time: 1.
05/06 09:06 EST - zacks.com
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.53 per share a year ago.
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.53 per share a year ago.
05/06 07:00 EST - businesswire.com
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company's proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic c.
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company's proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic c.
04/25 11:07 EST - zacks.com
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/17 08:00 EST - businesswire.com
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership.
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership.
04/04 16:30 EST - businesswire.com
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 10:15 a.m. ET. A live webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors &.
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 10:15 a.m. ET. A live webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors &.
03/27 23:40 EST - businesswire.com
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,7.
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,7.
03/27 09:51 EST - zacks.com
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
03/26 16:07 EST - businesswire.com
Stoke Therapeutics Announces Proposed Public Offering
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock. In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an ad.
Stoke Therapeutics Announces Proposed Public Offering
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock. In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an ad.
03/26 07:54 EST - investorplace.com
Why Is Stoke Therapeutics (STOK) Stock Up 99% Today?
Stoke Therapeutics (NASDAQ: STOK ) stock is soaring higher on Tuesday after the early-stage biopharmaceutical company posted positive clinical trial results. The new data comes from two open-label Phase 1/2a studies and two open-label extension (OLE) studies.
Why Is Stoke Therapeutics (STOK) Stock Up 99% Today?
Stoke Therapeutics (NASDAQ: STOK ) stock is soaring higher on Tuesday after the early-stage biopharmaceutical company posted positive clinical trial results. The new data comes from two open-label Phase 1/2a studies and two open-label extension (OLE) studies.
03/25 18:10 EST - zacks.com
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.65 per share a year ago.
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.65 per share a year ago.
03/25 16:01 EST - businesswire.com
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced landmark new data from two open-label Phase 1/2a studies and two open-label extension (OLE) studies of children and adolescents ages 2 to 18 with Dravet syndrome who were treated with STK-001. Data from these studies showed clinically meaningful effects, inclu.
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced landmark new data from two open-label Phase 1/2a studies and two open-label extension (OLE) studies of children and adolescents ages 2 to 18 with Dravet syndrome who were treated with STK-001. Data from these studies showed clinically meaningful effects, inclu.
03/25 16:01 EST - businesswire.com
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2023. Year End 2023 Financial Results As of December 31, 2023, Stoke had $201.4 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations to the end of 2025. Reve.
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2023. Year End 2023 Financial Results As of December 31, 2023, Stoke had $201.4 million in cash, cash equivalents, and marketable securities, which is anticipated to fund operations to the end of 2025. Reve.
02/29 09:51 EST - zacks.com
Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
02/26 11:01 EST - zacks.com
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02/25 13:37 EST - investorplace.com
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
02/19 14:31 EST - investorplace.com
Triple Threat: 3 Stocks to Buy for 3X Upside Potential
You want speculative stocks with upside potential up to 3X returns? I'm going to give them to you.
Triple Threat: 3 Stocks to Buy for 3X Upside Potential
You want speculative stocks with upside potential up to 3X returns? I'm going to give them to you.